



**Nadofaragene Firadenovec and Oportuzumab Monatox for
BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer**

Friday • November 20, 2020 • 9 am to 2 pm CT

Virtual Event – Zoom Webinar

https://us02web.zoom.us/webinar/register/WN_COZEBUZbQwuBtzPIO9ikQw

Time (CT)	Activity
9:00am – 9:20am	Meeting Convened and Opening Remarks Steven D. Pearson, MD, MSc, President, ICER
9:20am – 9:40am	Presentation of the Clinical Evidence Steven J. Atlas, MD, MPH Director, Primary Care Research & Quality Improvement Network, Massachusetts General Hospital Associate Professor of Medicine, Harvard Medical School
9:40am – 10:10am	Presentation of the Economic Model Daniel R. Touchette, PharmD, MA University of Illinois at Chicago College of Pharmacy
10:10am – 10:30am	Public Comments and Discussion
10:30am – 10:45am	Break
10:45am – 11:45am	Midwest CEPAC Vote on Clinical Effectiveness and Value
11:45am – 12:30pm	Lunch Break
12:30pm – 1:30pm	Policy Roundtable
1:30pm – 2:00pm	Reflections from Midwest CEPAC
2:00pm	Meeting Adjourned

ICER Staff and Consultants	
Steven J. Atlas, MD, MPH* Director, Primary Care Research & Quality Improvement Network, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School	Monica Frederick,* Program and Event Coordinator, ICER
Molly Beinfeld, MPH,* Research Lead, Evidence Synthesis, ICER	Avery Mckenna,* Research Assistant, ICER
Rick Chapman, PhD, MS,* Director of Health Economics, ICER	Steven D. Pearson, MD, MSc,* President, ICER
Mrinmayee Joshi, B. Pharm, PhD Student University of Illinois at Chicago College of Pharmacy	David M. Rind, MD, MSc,* Chief Medical Officer, ICER
Maggie O’Grady,* Program Manager, ICER	Daniel R. Touchette, PharmD, MA* University of Illinois at Chicago College of Pharmacy

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of Midwest CEPAC	
Eric Armbrecht, PhD (Chair)* Associate Professor, Saint Louis University Center for Health Outcomes Research, School of Medicine and College for Public Health & Social Justice	Yngve Falck-Ytter, MD, AGAF* Professor of Medicine, Case Western Reserve University; Chief, Gastroenterology and Hepatology VA Northeast Ohio Healthcare System, Cleveland
Alan Balch, PhD* Chief Executive Officer, Patient Advocate Foundation, National Patient Advocate Foundation	Bradley Martin, PharmD, PhD* Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy
Bijan Borah, PhD* Professor of Health Services Research, Mayo Clinic College of Medicine and Science	Timothy McBride, PhD* Co-Director, Center for Health Economics and Policy; Professor, Brown School, Washington University in St. Louis
Angela Brown, MPH* Chief Executive Officer, St. Louis Regional Health Commission (RHC)	Scott Micek, PharmD* Associate Professor, Pharmacy Practice, St. Louis College of Pharmacy
Kelly Buckland, MS* Executive Director, National Council on Independent Living	Reem Mustafa, MD, MPH, PhD* Associate Professor of Medicine, Division of Nephrology and Hypertension, and Director, Outcomes and Implementation Research, University of Kansas Medical Center
Aaron Carroll, MD, MS* Professor of Pediatrics; Associate Dean for Research Mentoring; Director, Center for Health Policy and Professionalism Research, Indiana University School of Medicine	Rachel Sachs, JD, MPH* Associate Professor of Law, Washington University in St. Louis
Stacie B. Dusetzina, PhD* Associate Professor of Health Policy, Ingram Associate Professor of Cancer Research, Vanderbilt University School of Medicine	Kurt Vanden Bosch, PharmD* System Formulary Manager, St. Luke’s Health System, Idaho

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
Stephanie Chisolm, PhD , Director of Education and Research, Bladder Cancer Advocacy Network	BCAN receives funding from FerGene and Merck.
Rachelle Dillon, PhD, Director , Clinical Operations, Sesen Bio	Dr. Rachelle Dillon is a full-time employee of Sesen Bio.
Leslie Fish, RPh, PharmD , Vice President of Clinical Pharmacy, IPD Analytics	Dr. Leslie Fish is a full-time employee of IPD Analytics.
John Gore, MD, MS, FACS , Associate Professor, Department of Urology; Adjunct Associate Professor, Department of Surgery, University of Washington	Dr. John Gore is an investigator for research sponsored by FerGene Pharmaceuticals unrelated to this review.
John W. McKnight, PharmD, BCPS , Vice President, HPS Clinical and Specialty Strategies	Dr. John McKnight is a full-time employee of Humana.
Aaron Mitchell, MD, MPH , Assistant Attending, Medical Oncologist, Memorial Sloan Kettering Cancer Center	No financial conflicts to disclose.
Karen Sachse, RN, MSN , Patient Advocate	Karen Sachse has received honorarium for participating in a patient focus group for FerGene.
Kristen Wachsmuth, DHSc, MBA , Senior Director, Medical Affairs & Clinical Development, FerGene	Dr. Kristen Wachsmuth is a full-time employee of FerGene.